Elicio Therapeutics Inc ELTX

$1.92 0.00 (—)

Valuation

Market cap
50,461,000
Revenue TTM
$0
Net income TTM
$-39,570,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
1.20

Trading

Volume
175,900
Avg volume
319,588
Day's range
$1.85 – $1.97
Shares out
26,282,000
Stochastic %K
65%
Beta
1.32
Analysts
Strong Sell
Price target
$14.50

Price

Company profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide trea...

Show more

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 209 0050
Website
https://elicio.com
Address
451 D Street, 5th Floor Suite 501, Boston, United States

Latest news

Stocktwits

Rosalie1224 Oct 3, 4:40 PM
$ELTX New Phase 1 combination trial expected in Q4 2026 and targeting metastatic pancreatic cancer..
0 replies
deucestwits Sep 30, 1:43 PM
$ELTX spoof bid 50k?
0 replies
nhyujm6 Sep 28, 4:33 PM
$ELTX https://www.biospace.com/deals/merck-inks-up-to-2-13b-deal-to-dine-with-scibrunch-gain-rights-to-preclinical-kras-inhibitor
1 replies
justiceforb_85 Sep 26, 8:27 PM
$ELTX hopefully presentation next month will give this company a much needed boost.
1 replies
nhyujm6 Sep 25, 6:13 PM
$ELTX ESMO: two possibilities: (1) OS from AMPLIFY-7P (2) A clearer responder phenotype / biological analysis that connects ELI-002 activity to the metastatic checkpoint hypothesis....
2 replies
justiceforb_85 Sep 25, 2:22 AM
$ELTX company needs to provide an update on combo tx with CPI. Think this has potential in both CRC and PDAC but not as monotherapy.
0 replies
StocksGoddess Sep 21, 6:09 PM
$ELTX
1 replies
highriskselllow Sep 16, 10:30 PM
$ELTX
1 replies